GlassScriptPhysician profile
Joseph H Oved
NPI 1932544806
$77,181.93
in general payments reported to CMS, 2019-2025
8 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $349 · 2023: $13K · 2024: $34K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Travel and Lodging: $10K · Food and Beverage: $6,931 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,031.31 |
| Travel and Lodging | $10,292.57 |
| Food and Beverage | $6,931.04 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $58,592.50 | 2022-2025 | |
| Amgen INC. | $9,092.04 | 2024 | Actimmune |
| Grifols USA, LLC | $7,280.12 | 2024 | Xembify |
| Celgene Corporation | $1,403.17 | 2024 | |
| Stryker Corporation | $417.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $274.39 | 2024 | |
| Medexus Pharma, INC. | $122.71 | 2025 | Grafapex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Oved listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.